title: ECHOGENIC LIPSOMES FOR TARGETED DRUG DELIVERY.
abstract: Echogenic immunoliposomes (ELIP) are under development to enable ultrasound-controlled drug delivery. Mechanistic studies in vitro have revealed that stable cavitation is correlated with enhanced recombinant tissue Plasminogen Activator (rt-PA) thrombolysis, yet strategies to optimize the occurrence of such bubble activity and avoid potential harmful bioeffects have yet to be identified. Stable cavitation is characterized by bubbles pulsating gently in response to the time-varying acoustic pressure in an ultrasound field. A review of in vitro sonothrombolysis studies utilizing commercial US contrast agent or echogenic liposomes loaded with rt-PA to nucleate stable cavitation will be presented. Strategies for the development of ultrasound-enhanced thrombolysis and drug delivery will be discussed.
authors.affiliation: Department of Biomedical Engineering, University of Cincinnati, 231 Albert Sabin Way, Medical Sciences Building, Room 6167, Cincinnati, OH, 45267-0586, USA.
authors.forename: Christy K
authors.initials: CK
authors.lastname: Holland
authors.forename: David D
authors.initials: DD
authors.lastname: McPherson
references.citation: J Pharm Sci. 1996 May;85(5):486-90
references.pmid: 8742939
references.citation: Invest Radiol. 2002 Apr;37(4):215-21
references.pmid: 11923644
references.citation: Radiology. 1992 Nov;185(2):453-6
references.pmid: 1410353
references.citation: Am J Cardiol. 1998 Jun 18;81(12A):58G-61G
references.pmid: 9662229
references.citation: Ultrasound Med Biol. 2007 Apr;33(4):576-83
references.pmid: 17337113
references.citation: Ultrasound Med Biol. 2006 Aug;32(8):1257-67
references.pmid: 16875959
references.citation: Ultrasound Med Biol. 2008 Sep;34(9):1421-33
references.pmid: 18378380
references.citation: Proc Natl Acad Sci U S A. 1990 Apr;87(7):2448-51
references.pmid: 2157200
references.citation: Thromb Res. 2009 Jul;124(3):306-10
references.pmid: 19217651
references.citation: J Am Soc Echocardiogr. 2000 Jun;13(6):608-14
references.pmid: 10849515
references.citation: Circulation. 1996 Dec 15;94(12):3334-40
references.pmid: 8989148
references.citation: J Control Release. 2010 Jun 15;144(3):288-95
references.pmid: 20202474
references.citation: Neuro Oncol. 2000 Jan;2(1):45-59
references.pmid: 11302254
references.citation: J Liposome Res. 2008;18(2):95-112
references.pmid: 18569446
references.citation: Thromb Res. 2008;121(5):663-73
references.pmid: 17854867
references.citation: J Mol Biol. 1965 Aug;13(1):238-52
references.pmid: 5859039
references.citation: J Drug Target. 2007 Feb;15(2):109-14
references.pmid: 17365281
references.citation: Ultrasound Med Biol. 2002 Mar;28(3):339-48
references.pmid: 11978414
references.citation: Semin Interv Cardiol. 1996 Mar;1(1):8-16
references.pmid: 9552480
references.citation: J Pharm Sci. 2001 Dec;90(12):1917-26
references.pmid: 11745750